Economic Burden of Macrophage Activation Syndrome (MAS) in Patients with Still’s Disease (Systemic Juvenile Idiopathic Arthritis (sJIA) and Adult-onset Still’s Disease (AOSD): Analysis of a US National Administrative Claims Database

This poster presentation is under embargo until 12 June 2025, as per congress regulations.

Please subscribe using the button below to receive a notification when the material becomes available:

Publication

ACR •
29 October, 2025 •
•

PAXIS: A Randomized, Double-Blind, Placebo-Controlled, Dose Finding Phase 2 Study (Part 1) Followed by an Open-Label Period (Part 2) to Assess the Efficacy and Safety of Pacritinib in Patients with VEXAS Syndrome

David B. Beck, Mael Heiblig, Sinisa Savic, Marcela A. Ferrada, Arsene Mekinian, Onima Chowdhury, Danielle Hammond, Lachelle D. Weeks, Carmelo Gurnari, Yohei Kirino , Sophie Georgin-Lavialle, Sarah A. Buckley, Bryan G. Harder, Sandra Goble, Matthew J. Koster

Publication

ACR •
27 October, 2025 •
•

Emapalumab Treatment for Patients with Differing Presentations of Macrophage Activation Syndrome (MAS) Secondary to Still’s Disease: Results from a Pooled Analysis of Two Prospective Trials

Alexei A. Grom, Sebastian J. Vastert, Jordi Antón, Pierre Quartier, Bruno Fautrel, Paul Brogan, Edward M. Behrens, Melissa Elder, Francesca Minoia, Pavla Dolezalova, Robert Biesen, Masaki Shimizu, Uwe Ullmann, Adnan Mahmood, Andrew Danquah, Elena Burillo, Marco Petrimpol, Steve Mallett, Brian D. Jamieson, Fabrizio De Benedetti

Publication

ACR •
26 October, 2025 •
•

Baseline Pharmacodynamic Markers and Response to Emapalumab in Children and Adults with Macrophage Activation Syndrome (MAS) in Still’s Disease: Results from a Pooled Analysis of Two Prospective Trials

Edward M. Behrens, Sebastian J. Vastert, Jordi Antón, Pierre Quartier, Bruno Fautrel, Paul Brogan, Melissa Elder, Francesca Minoia, Pavla Dolezalova, Robert Biesen, Masaki Shimizu, Uwe Ullmann, Adnan Mahmood, Andrew Danquah, Elena Burillo, Marco Petrimpol, Steve Mallett, Brian D. Jamieson, Alexei A. Grom, Fabrizio De Benedetti

Publication

PReS •
19 September, 2025 •
•

Changes in Pharmacodynamic Markers (PD) in Response to Emapalumab in Children and Adults with Macrophage Activation Syndrome (MAS) in Still’s Disease: Results from a Pooled Analysis of Two Prospective Trials

Sebastian J. Vastert, Jordi Antón, Pierre Quartier, Bruno Fautrel, Paul Brogan, Edward M. Behrens, Melissa Elder, Francesca Minoia, Pavla Dolezalova, Robert Biesen, Masaki Shimizu, Uwe Ullmann, Adnan Mahmood, Andrew Danquah, Elena Burillo, Marco Petrimpol, Steve Mallett, Brian D. Jamieson, Alexi Grom, Fabrizio De Benedetti

Available materials

Oral Presentation

Symposium

APLAR •
5 September, 2025 •
•

Management of MAS and Still’s Disease: Challenges and opportunities

Masaki Shimizu, Fabrizio De Benedetti

Available materials

Slides Video

Publication

APLAR •
3 September, 2025 •
•

Efficacy and Safety of Emapalumab for Treating Macrophage Activation Syndrome in Still’s disease: A Pooled Analysis of Two Prospective Trials

Masaki Shimizu, Alexei A. Grom, Uwe Ullmann, Adnan Mahmood, Josefin Blomkvist, Brian D. Jamieson, Fabrizio De Benedetti

Available materials

Poster

Publication

EULAR •
13 June, 2025 •
•

Exposure–safety analysis from two clinical trials of emapalumab in patients with macrophage activation syndrome in Still’s disease

Rafael T. Krmar, Brian Jamieson, Kristina Star, Anna Stoltenberg, Adnan Mahmood, Uwe Ullmann, Fabrizio De Benedetti, Alexei A. Grom,, Axel Facius, Patrick Brossard

Available materials

Poster